CA-GLOBALLOGIC-INC
GlobalLogic Inc. , a leader in Digital Product Engineering, today announced that it has completed the acquisition of Meelogic Consulting AG , a Germany-based software engineering services firm with deep expertise in Healthcare, Automotive, and other key industries undergoing significant digital transformation. This acquisition is part of GlobalLogic’s ongoing strategy to strengthen its position in high-growth verticals by expanding design, architecture, and software engineering capabilities. Additionally, with its exceptional reputation in the DACH (Austria, Germany, Switzerland) region, Meelogic follows GlobalLogic’s other recent acquisitions in bolstering the overall delivery footprint in strategic European geographies.
Meelogic was founded in 2011 by seasoned engineering visionaries who sought to establish a firm that would maintain a culture of innovation and agility while delivering top quality, enterprise-class software products for large, blue-chip clients. This disciplined focus has enabled the company to expand to five locations, with headquarters in Berlin; other German offices in Cologne and Stuttgart; and engineering centers in Szczecin and Bydgoszcz, Poland. Further, the firm’s work has garnered both customer accolades and a prominent role in grassroots industry forums on emerging technologies, such as Blockchain and IoT.
“We’ve been particularly selective when considering potential acquisitions to realize our vision for strategic expansion,” said Shashank Samant, CEO, GlobalLogic. “We look for cultural fit, geographic alignment, and deep software engineering skills and technical competency. We seek businesses that demonstrate a keen eye for creative problem-solving as well as an unshakable commitment to delivering above and beyond customer expectations. Meelogic possesses all of these attributes. They have built an incredible company with a roster of talented engineers who are focused on important and burgeoning technologies and exemplify the ingenuity and drive for success. We’re delighted to have the Meelogic team on board as our new colleagues.”
“Through smart growth strategies and a relentless focus on creating value for our customers, we’ve been able to become integral, trusted partners in their most important initiatives,” said Ayana Alemu, CEO, Meelogic. “This is an incredible opportunity for us to offer our clients a broader set of capabilities and access to greater scale. We’re thrilled to be joining forces with GlobalLogic to take our combined organization to a new level of innovation and growth.”
Meelogic’s customer experience includes projects in various markets that align directly with GlobalLogic’s business focus, especially in automotive, healthcare and medical technology, digital media, information technology, and telecommunications. The company’s customer relationships are comprised of top global brands. This is GlobalLogic’s second European acquisition in six months, reflecting the strategic importance of this region.
Terms of the transaction were not disclosed.
Useful GlobalLogic Links:
GlobalLogic: http://www.globallogic.com
LinkedIn: https://www.linkedin.com/company/globallogic/
Facebook: https://www.facebook.com/GlobalLogic/
Twitter: https://twitter.com/GlobalLogic
About GlobalLogic
GlobalLogic is a leader in digital product engineering. We help our clients design and build innovative products, platforms, and digital experiences for the modern world. By integrating strategic design, complex engineering, and vertical industry expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the communications, automotive, healthcare, technology, media and entertainment, manufacturing, and semiconductor industries. www.globallogic.com
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
About MEELOGIC
Meelogic Consulting AG develops IT solutions for a mobile and interconnected world based on an in-depth understanding of technologies and markets in the digital age. The company was founded in 2011 in Berlin with additional locations in Szczecin (Poland), Cologne, Stuttgart and Bydgoszcz (Poland). Meelogic is now working with international teams for well-known customers in their respective industries comprising automotive, medical technology, media, transport, energy, telecommunications, information technology, logistics and e-commerce.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005022/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom